The mechanism of beta-glycerophosphate action in mineralizing chick limb-bud mesenchymal cell cultures.
Differentiating chick limb-bud mesenchymal cells plated in micromass culture form a cartilage matrix that can be mineralized in the presence of 4 mM inorganic phosphate (Pi), and 1 mM calcium. Previous studies showed that when beta-glycerophosphate (beta GP) is used in place of Pi, the mineral crystals formed are larger and differ in distribution. The present study shows that the difference in distribution is not associated with alterations in cell proliferation, protein synthesis, or with collagen, proteoglycan core protein, or alkaline phosphatase gene expression. Cultures with 2.5, 5, and 10 mM beta GP did show different levels of alkaline phosphatase activity, and in the presence of low (0.3 mM) Ca had different Pi contents (4, 6 and 9 mM, respectively), indicating that the increase in CaxP product may in part be responsible for the altered pattern of mineralization. However, cultures with beta GP in which alkaline phosphatase activity was inhibited with levamisole still had an altered mineral distribution as revealed by Fourier transform-infrared (FT-IR) microspectroscopy. The presence of a casein kinase II-like activity in the mineralizing cultures, the ability of specific inhibitors of this enzyme to block mineralization, and the known ability of beta GP to block phosphoprotein phosphatase activity suggests that altered patterns of matrix protein phosphorylation may influence mineral deposition in these cultures.
Boskey
A L
AL
Hospital for Special Surgery, Cornell University Medical College, New York, New York, USA.
Guidon
P
P
Doty
S B
SB
Stiner
D
D
Leboy
P
P
Binderman
I
I
D000469:Alkaline Phosphatase / Q000378:metabolism; D000818:Animals; D002358:Cartilage, Articular / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002642:Chick Embryo; D004247:DNA / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005326:Fetal Proteins / Q000096:biosynthesis; D018507:Gene Expression Regulation, Developmental / Q000187:drug effects; D005994:Glycerophosphates / Q000494:pharmacology*; D006868:Hydrolysis; D018878:Limb Buds / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008648:Mesoderm / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008903:Minerals / Q000378:metabolism*; D013379:Substrate Specificity
D004791:Enzyme Inhibitors; D005326:Fetal Proteins; D005994:Glycerophosphates; D008903:Minerals; D004247:DNA; D000469:Alkaline Phosphatase; C031463:beta-glycerophosphoric acid